66 filings
8-K
ME
23andMe Holding Co - Ordinary Shares
24 May 24
Departure of Directors or Certain Officers
4:06pm
8-K
ME
23andMe Holding Co - Ordinary Shares
23 May 24
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
4:07pm
8-K
ME
23andMe Holding Co - Ordinary Shares
10 May 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
ME
23andMe Holding Co - Ordinary Shares
18 Apr 24
23andMe announces CEO’s intention to pursue a potential take-private
8:07am
8-K
ME
23andMe Holding Co - Ordinary Shares
29 Mar 24
Departure of Directors or Certain Officers
12:46pm
8-K
pqbthv bvur2uri01o
7 Feb 24
23andMe Reports Third Quarter Fiscal 2024 Financial Results
4:03pm
8-K
23mo ep702m
31 Jan 24
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
7:50am
8-K
qnylf4wurc ooen
8 Jan 24
Regulation FD Disclosure
7:45am
8-K/A
w07 xxuik
1 Dec 23
Regulation FD Disclosure
4:06pm
8-K
xw6br2
13 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
1d5cybg
8 Nov 23
23andMe Reports Second Quarter Fiscal 2024 Financial Results
4:29pm
8-K
yy5wc xmwe
6 Nov 23
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
8:15am
8-K
xhsx0
30 Oct 23
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
4:05pm
8-K
q4e5 1rv0w3i62k
27 Oct 23
Departure of Directors or Certain Officers
4:06pm
8-K
jpcb5cakpte
10 Oct 23
Regulation FD Disclosure
4:17pm
8-K
8y0q6g3
19 Sep 23
Departure of Directors or Certain Officers
4:06pm
8-K
n6osyuk3
11 Sep 23
Departure of Directors or Certain Officers
4:06pm
8-K
b9uaf3046ltkfemnm01y
1 Sep 23
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
12:00am
8-K
lureo9 yl
8 Aug 23
23andMe Reports FY2024 First Quarter Financial Results
4:10pm
8-K
l40egquok0o98bv6h i1
9 Jun 23
Cost Associated with Exit or Disposal Activities
4:05pm